Anxo Pharmaceutical Co (ROCO:6677) EV-to-EBIT : 44.05 (As of Apr. 30, 2024)

Anxo Pharmaceutical Co EV-to-EBIT Chart

Anxo Pharmaceutical Co Annual Data
	Trend	Dec13	Dec14	Dec15	Dec16	Dec17	Dec18	Dec19	Dec20	Dec21	Dec22
EV-to-EBIT		Get a 7-Day Free Trial					44.26	49.18	33.52	52.24	205.79

Anxo Pharmaceutical Co Semi-Annual Data
	Dec14	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
EV-to-EBIT	Get a 7-Day Free Trial												-	52.24	-	205.79	-

Competitive Comparison of Anxo Pharmaceutical Co's EV-to-EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Anxo Pharmaceutical Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Anxo Pharmaceutical Co's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Anxo Pharmaceutical Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Anxo Pharmaceutical Co's EV-to-EBIT falls into.

Anxo Pharmaceutical Co EV-to-EBIT Calculation

Anxo Pharmaceutical Co's EV-to-EBIT for today is calculated as:

Anxo Pharmaceutical Co's current Enterprise Value is NT$3,169.1 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Anxo Pharmaceutical Co's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 was NT$71.9 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Anxo Pharmaceutical Co  (ROCO:6677) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Anxo Pharmaceutical Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2023 is calculated as:

Anxo Pharmaceutical Co's Enterprise Value for the quarter that ended in Jun. 2023 was NT$4,340.8 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Anxo Pharmaceutical Co's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 was NT$71.9 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Anxo Pharmaceutical Co EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Anxo Pharmaceutical Co's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Anxo Pharmaceutical Co (ROCO:6677) Business Description